Skip to main content

Danaher Value Stock - Dividend - Research Selection

Danaher

ISIN: US2358511028 , WKN: 866197

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company\'s Life Sciences segment provides laser scanning, compound, surgical, and other stereo microscopes. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors. Its Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and flow cytometry products. The company offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians\' offices, reference laboratories, and other critical care settings. Its Dental segment provides consumables, equipment, and services to diagnose, treat, and prevent disease and ailments of the teeth, gums, and supporting bone. This segment offers implant systems, dental prosthetics, and associated treatment planning software; orthodontic bracket systems and lab products; endodontic systems and related consumables; restorative materials and instruments; infection prevention products; digital imaging systems and software; air and electric powered handpieces, and consumables; and treatment units. Its Environmental & Applied Solutions segment offers instrumentation, services, and disinfection systems to analyze, treat, and manage water in residential, commercial, industrial, and natural resource applications. This segment also provides equipment, software, services, and consumables for packaging, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


OmniAb Names Amechi Nwachuku Chief Operating Officer

2026-07-13
EMERYVILLE, Calif., July 13, 2026--OmniAb, Inc. (NASDAQ:OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, announces that it has appointed Amechi Nwachuku to the newly-created position of Executive Vice President and Chief Operating Officer, effective today. Mr. Nwachuku will be primarily responsible for managing the strategy, operations and commercial maximization of xPloration®, OmniAb’s proprietary, innovative high-throughp

Cell Isolation Market/Cell Separation Market by Product, Cell Type, Source, Technique, Application, End User, Competition, Region - Global Forecast to 2031

2026-07-13
The cell isolation market is projected to grow from USD 4.39 billion in 2026 to USD 7.97 billion by 2031, with a CAGR of 12.7%. Key drivers include the expansion of cell and gene therapy, rising demand for immune cell isolation, and increased adoption of automated systems. Techniques like centrifugation, magnetic and fluorescence-activated cell sorting, and microfluidics enable enrichment of immune, stem, and tumor cells. The consumables segment is set to lead growth, propelled by the recurring

Mar Vista U.S. Quality Premier Portfolio Q2 2026 Portfolio Activity

2026-07-12
Mar Vista's U.S. Quality Premier strategy returned +10.15% net-of-fees in the second quarter of 2026. Read more here.

Abbott Labs Vs. Danaher: Abbott’s Everyday Products Beat Danaher’s Slumping Biotech Equipment

2026-07-10
Abbott and Danaher both reported Q1 2026 results, but the businesses underneath those numbers point in opposite directions, and choosing the wrong one right now costs more than just a few percentage points of return.

Danaher Is Getting Better, But The Stock Still Isn't Cheap

2026-07-10
Danaher stock analysis: Q1 results, bioprocessing growth, diagnostics weakness, and valuation vs. intrinsic value ($172.91). Click here to read more on DHR.

Jim Cramer on Danaher: “I Don’t Want You Anywhere Near That One”

2026-07-10
Danaher Corporation (NYSE:DHR) was among the stocks Jim Cramer discussed during Mad Money, as he called the growing wave of stock offerings and debt issuance a threat to the bull market. Expressing their wish to diversify, a caller inquired about the stock, and Cramer commented: Danaher’s been a huge disappointment, and we managed to get […]

Qiagen M&A Fever Builds: KKR, EQT, Advent Explore Possible Takeover

2026-07-10
Private equity giants circle Qiagen (QGEN) with potential bids of $50/share. Get the details on the molecular diagnostics buyout.

Danaher (DHR) Wins CE Mark For Access P Tau217 Assay, Is The Stock A Bargain?

2026-07-09
Beckman Coulter Diagnostics, part of Danaher (DHR), has received CE Mark under IVDR for its Access p-Tau217 blood assay, drawing fresh attention to the stock’s diagnostics exposure and valuation. See our latest analysis for Danaher. Against this diagnostic milestone, Danaher’s share price has softened this year. The stock is at $190.77 with a year to date share price return down 17.2%, while the 1 year total shareholder return is down 4.37%. This suggests sentiment has cooled despite interest...

VTRS or DHR: Which Is the Better Value Stock Right Now?

2026-07-09
VTRS vs. DHR: Which Stock Is the Better Value Option?

Illumina: While You Chased AI, This Healthcare Stock Built A $30B Moat

2026-07-09
Illumina dominates genomics sequencing with recurring growth, NovaSeq X catalysts, and improving margins/FCF. Click to know why the ILMN shares look promising.